The key products and services being delivered under this federal contract IDV award are Oxervate, an ophthalmic solution used to treat neurotrophic keratitis. The prime contractor, Dompe U.S. Inc., a foreign-owned for-profit pharmaceutical manufacturer, has received a single-award Blanket Purchase Agreement (BPA) from the Department of Veterans Affairs (VA) National Acquisition Center with a ceiling value of $49,717.65 and a period of performance through February 18, 2026.
This BPA is issued against the GSA Pharmaceuticals and Drugs schedule (FSS-61-IB), and Dompe has also held other IDV contracts with the VA to provide Oxervate and other pharmaceutical products, including a previous $10 million BPA and a $5 million FSS schedule contract. The VA has used these contract vehicles to issue firm fixed-price delivery orders to Dompe to fulfill urgent medication needs at VA facilities across the country, including during the COVID-19 pandemic response. No set-aside designations were used for these awards.
Generated 2/19/25, 9:07 AM